A condition of blood plasma that produces altered antibodies that increase the risk of blood cancers and other conditions.
Update Date: 30.12.2025
Monoclonal gammopathy of undetermined significance, also called MGUS, is a condition caused by the development of altered plasma cells. A plasma cell is a type of white blood cell that usually produces disease-fighting antibodies.
In MGUS, plasma cells in bone marrow produce antibodies called monoclonal proteins that circulate in the blood. These antibodies also may be called M proteins, myeloma proteins or paraproteins.
MGUS is not itself a disease, but having MGUS increases the risk of developing cancer of the plasma cells and related conditions.
There is no treatment for MGUS. With regular checkups, a healthcare team monitors for changes in M protein levels, increases in altered plasma cells, and signs of cancer or other diseases.
People with MGUS usually don't have symptoms. Most often, the condition is found with blood tests done for regular checkups or for diagnosing another condition.
Experts don't know what causes MGUS. Genes within plasma cells may change because of a number of factors.
Factors that increase your risk of developing MGUS include:
Each year, about 1% of people with MGUS develop cancer of the plasma cells or related conditions. These include the following:
M proteins may cause disease in tissues and change how organs function. If this type of M protein–related condition develops, it's called monoclonal gammopathy of clinical significance. Affected areas of the body may include the:
Other complications include:
MGUS is usually discovered with blood tests done for other conditions or for regular checkups. When M proteins are found, you have more tests to better understand the condition and to see if there are signs of cancer or other organ damage. These tests include:
MGUS doesn't require treatment. Your care team schedules regular checkups to repeat blood and urine tests to find any increases in M proteins. You may have additional tests if a change in M proteins suggests an increased risk of cancer or other diseases.
You'll likely have a first follow-up exam within 3 to 6 months after a diagnosis of MGUS. Your healthcare team determines how often to repeat exams depending on the risk of MGUS leading to cancer or other diseases.
Talk with your healthcare professional if you have new symptoms. Symptoms to watch for include:
If you develop osteoporosis, you may be prescribed a medicine called a bisphosphonate to slow the loss of bone tissue. Examples include alendronate (Binosto, Fosamax), risedronate (Actonel, Atelvia), zoledronic acid (Reclast, Zometa) and ibandronate.
Your healthcare professional may refer you to a doctor who specializes in blood conditions, called a hematologist.
Here's information to help you get ready for your appointment.
Ask a family member or friend to go with you. Someone who's with you can help you remember the information you get.
Make a list of:
For MGUS, basic questions to ask your health professional include:
Be sure to ask all the questions you have.
Your healthcare professional is likely to ask you questions, including:
© 2026 Mayo Foundation for Medical Education and Research. All rights reserved. Terms of Use